Systemic effects of COPD: Just the tip of the iceberg

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 5, Issue 4, 2008, Pages 205-206

  Agusti, Alvar ^a  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

Chronic Bronchitis; Emphysema; Inflammation; Sedentarism; Symptoms

Indexed keywords

ANXIETY; CARDIOVASCULAR DISEASE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DEPRESSION; EDITORIAL; EXERCISE TOLERANCE; HUMAN; INFLAMMATION; LUNG EMPHYSEMA; METABOLIC DISORDER; MUSCLE DISEASE; OSTEOPOROSIS; PRIORITY JOURNAL; SITTING; SYMPTOMATOLOGY;

COMORBIDITY; FEMALE; HUMANS; INCIDENCE; MALE; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 48749091182     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.1080/15412550802237317     Document Type: Editorial

References (18)

1. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, Van WC, Zielinski J. 2007. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176:532-555.
2. Agusti A. Thomas A. Neff lecture. Chronic obstructive pulmonary disease: a systemic disease. Proc Am Thorac Soc 2006; 3:478-481.
3. Celli BR, MacNee W, Agusti AG, Anzueto A, Berg BR, Buist AS, Calverley P, Chavannes N, Dillard T, Fahy B, Fein A, Heffner J, Lareau SC, Meek P, Martinez F, McNicholas WT, Muris J, Austergard E, Pauwels R, Rennard S, Rossi A, Siafakas N, Tiep B, Vestbo J, Wouters E, ZuWallack R. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23:932-946.
4. Burrows B, Fletcher CM, Heard BE, Jones NL, Wootliff JS. 1966. The emphysematous and bronchial types of chronic airways obstruction. A clinicopathological study of patients in London and Chicago. Lancet 1966; 1:830-835.
5. Schols AM, Soeters PB, Dingemans AM, Mostert R, Frantzen PJ, Wouters EF. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis 1993; 147:1151-1156.
6. Agusti AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. 2003. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 21:347-360.
7. Fabbri LM, Rabe KF. 2007. From COPD to chronic systemic inflammatory syndrome? Lancet 370:797-799.
8. Decramer M, Rennard S, Troosters T, Mapel DW, Giardino ND, Mannino D, Wouters E, Sethi S, Cooper CB. COPD as a lung disease with systemic consequences - clinical impact, mechanisms, and potential for early intervention. J COPD 2008; (In press)
9. Agusti A. Systemic effects of chronic obstructive pulmonary disease: What we know and what we don't know (but should). Proc Amer Thoracic Soc 2007; 4:522-525.
10. Sin DD, Lacy P, York E, Man SFP. 2004. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170:760-765.
11. Sin DD, Man SFP, Marciniuk DD, Ford G, FitzGerald M, Wong E, York E, Mainra RR, Ramesh W, Melenka LS, Wilde E, Cowie RL, Williams D, Gan WQ, Rousseau R, B. i. C. I. for the ABC (Advair). The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177:1207-1214.
12. Pinto-Plata, V, Toso J, Lee K, Bilello J, Mullerova H, De Souza M, Vessey R, Celli B. Use of proteomic patterns of serum biomarkers in patients with chronic obstructive pulmonary disease: correlation with clinical parameters. Proc Amer Thoracic Soc 2006; 3:465-466.
13. Sims MW, Tal-Singer RW, Kierstein S, Musani AI, Beers MF, Panettieri, Jr. RA, Haczku A. Chronic obstructive pulmonary disease and inhaled steroids alter surfactant protein D (SP-D) levels: a cross-sectional study. Respir Res 2008; 9:13.
14. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PMA, Celli BR, Jones PW, Mahler DA, Make B, Miravitlles M, Page CP, Palange P, Parr P, Pistolesi M, Rennard SI, Rutten-Van Molken MP R, Stockley R, Sullivan SD, Wedzicha JA, Wouters EF, and on behalf of the American Thoracic Society/European Respiratory Society Task Force on outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 31:416-469.
15. Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, Edwards L, Hagan G, Knobil K, Lomas DA, MacNee W, Silverman EK, Tal-Singer R, the E. i. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE). Eur Respir J 2008; 09031936.
16. Fabbri LM, Luppi F, Beghe B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J 2008; 31:204-212.
17. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 2005; 294:716-724.
18. Au DH. Use of β blockers in patients with COPD. Thorax 2008; 63:296-298.